Jin Liang, Wang Yu, Xiong Qiyan, Chen Qingmei, Li Jianping, Zhu Aihua, Cao Rongyue, Wu Jie, Liu Jingjing
Minigene Pharmacy Laboratory, Biopharmaceutical College, China Pharmaceutical University, Tongjia Xiang 24, Nanjing 210009, PR China.
Vaccine. 2007 Mar 1;25(11):2043-50. doi: 10.1016/j.vaccine.2006.11.052. Epub 2006 Dec 8.
To improve the weak immunogenicity of peptide P277, the recombinant expression plasmid pET28-Hsp65-6 x P277 was constructed by inserting 5 x P277 which was amplified by PCR into the vector pET28-Hsp65-P277. It was transformed into Escherichia coli BL21 (DE3) and the fusion protein (Hsp65-6 x P277) was expressed effectively as soluble protein after inducing by lactose. The fusion protein was purified by means of cell disruption, ammonium sulfate precipitation, double-distilled H2O dialysis, DEAE52-cellulose column chromatography, and then used to immunize female NOD mice with three i.n. inoculations in the absence of adjuvants. Serum samples from the immunized mice were collected at 3 weeks interval. Antibodies against P277 and HSP65 were detected in immunized mice sera by enzyme-linked immunosorbent assay (ELISA) and Western blot. Specific antibodies were successfully induced and lasted for more than 20 weeks in animals immunized with the fusion protein via intranasal route even in the absence of adjuvants.
为提高肽P277较弱的免疫原性,通过将经PCR扩增的5×P277插入载体pET28-Hsp65-P277构建重组表达质粒pET28-Hsp65-6×P277。将其转化至大肠杆菌BL21(DE3)中,经乳糖诱导后,融合蛋白(Hsp65-6×P277)作为可溶性蛋白有效表达。融合蛋白经细胞破碎、硫酸铵沉淀、双蒸水透析、DEAE52-纤维素柱层析纯化,然后用于在无佐剂的情况下经鼻内接种三次免疫雌性NOD小鼠。每隔3周收集免疫小鼠的血清样本。通过酶联免疫吸附测定(ELISA)和蛋白质印迹法检测免疫小鼠血清中针对P277和HSP65的抗体。即使在无佐剂的情况下,经鼻内途径用融合蛋白免疫的动物中也成功诱导出特异性抗体,且持续超过20周。